6 Peptide Biotech Stocks to watch for future.
$BCYC
•Tumor-targeting bicyclic peptides
•Oncology + peptide-drug conjugates
•Could attract major pharma buyouts if trials succeed
$ENTX
•Oral peptide delivery—no injections needed
•Osteoporosis & metabolic disease drugs
•Potential to disrupt $100B injectable peptide market
$LSTA
•Peptides that help chemotherapy drugs penetrate tumors
•Oncology-focused with Phase 2/3 catalysts
$CUE
•Peptide-MHC molecules activate immune cells
•Precision immunotherapy for cancer & autoimmune diseases
$VTGN
•Neuropeptide nasal sprays
•Rapid-acting treatments for social anxiety disorder
•Huge potential psychiatric market if trials succeed
$PEPG
•Peptide-enhanced delivery of RNA therapies
•Focus on rare genetic diseases, e.g., Duchenne muscular dystrophy
•Solves one of biotech’s biggest challenges: getting therapies inside cells efficiently
•Could become a major platform play if delivery technology proves successful
The peptide revolution is already underway:
•GLP-1 drugs proved the market is massive
•AI-designed peptides accelerate drug discovery
•Small-cap peptide biotech companies often become multi-bagger winners after clinical successes
High risk, high reward — clinical-stage biotechs are volatile. But the next biotech cycle could be defined by peptides.
